Orthofix saw net sales of $205.6 million in the third quarter, a 5% increase year over year, according to financial results posted Nov. 4.
Six things to know:
1. Net sales of $205.6 million include revenue from the discontinued M6 artificial disc. Excluding M6, quarterly sales were $203.4 million.
2. U.S. spinal fixation sales increased 8% year over year, and procedure volume grew 10% year over year.
3. Bone growth therapies saw net sales of $61.2 million, a 6% increase year over year.
4. Global orthopedic sales increased 6% year over year with $33.6 million.
5. Orthofix saw a net loss of $22.8 million.
6. Orthofix narrowed its 2025 full-year guidance and expects pro forma net sales to range between $810 million to $814 million.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
